中南医学科学杂志2017，Vol.45Issue(3)：283-287,5.DOI:10.15972/j.cnki.43-1509/r.2017.03.017
弥漫大B细胞淋巴瘤中MYC和BCL-2蛋白共表达的临床病理意义
The clinicopathological significances of MYC and BCL-2co-expression in diffuse large B cell lymphoma
胡名娟 1李国伟 1欧阳小明2
作者信息
- 1. 广州市花都区人民医院病理科,广东 广州510800
- 2. 广州医科大学附属第二医院病理科
- 折叠
摘要
Abstract
Objective To assay the expression of MYC and BCL-2 proteins in diffuse large B-cell lymphoma (DLBCL),and to investigate the clinicopathological significances of MYC/BCL-2 co-expression in DLBCL.Methods Archived 76 DLBCL,NOS were collected and analyzed retrospectively.The clinicopathological characteristics,including Ann Arbor staging,the international prognostic index (IPI) score,Hans's classification and therapeutic effects,were re-evaluated.The co-expression of MYC/BCL-2 was detected by immunohistochemical staining using EnVision detection system.Results MYC or BCL-2 expression could be detected in 55 cases (72.4%) and 41 cases (53.9%),respectively.The co-expression of MYC/BCL-2 was observed in 33 cases (43.4%).There was a close relationship found between co-expression of MYC/BCL-2 and higher Ann Arbor staging (P=0.011),or worse therapeutic effect of patient (P=0.002).However,co-expression of MYC/BCL-2 was not correlated to other clinicopathological features,such as tumor site and Hans's classification.In addition,there was no correlation found among IPI score and all of clinicopathological features of DLBCL in this study.Conclusions Co-expression of MYC/BCL-2 in tumor cells might be a specific immunohistochemical phenotype of DLBCL,and combined with standard IPI score,which might be a valuable prognostic factor for DLBCL patients with rituximab treatment.关键词
弥漫大B细胞淋巴瘤/MYC蛋白/BCL-2蛋白/预后Key words
Diffuse large B-cell lymphoma/MYC/BCL-2/prognosis分类
医药卫生引用本文复制引用
胡名娟,李国伟,欧阳小明..弥漫大B细胞淋巴瘤中MYC和BCL-2蛋白共表达的临床病理意义[J].中南医学科学杂志,2017,45(3):283-287,5.
